Synergistic Efficacy of an Interleukin 2 Analog and Antitumor Antigen Antibody

Principal Investigator Program DirectorLastFirstMiddleChenRidong Abstract InterleukinILimmunotherapy can result in remarkable long term responses in some cancer patients by stimulating the immune response to kill tumor cellsHowevercurrent rILtherapy is limited to highly selected patients due to its requirements for high and frequent dosingwhich can result in severe side effectsMoreoverrILalso activates CDregulatory T cellswhich suppress the immune responseTo ameliorate the liabilities of the current rILdrugwe have designed a long acting ILanalog that selectively preserves immune response activationCDTNK cellswithout activating regulatory T cells and endothelial cellstherebyminimizing immune suppression and vascular leak syndromeWe propose to optimize combination of rILanalog treatment plus antitumor antibody to safely and effectively kill tumor cells via a concerted innate and adaptive response involving neutrophilsNK cellsmacrophagesand CDT cellsIn this studythe Specific Aim is to use the syngeneic mouse model of BFto determine whether the combination of the proprietary ILanalog with an antitumor antigen antibody effectively eradicates established tumors without inducing adverse side effectsOur long term goal is to develop the proprietary ILanalog as a safe immunotherapy to cure cancer or extend survival of patients Principal Investigator Program DirectorLastFirstMiddleChenRidong NarrativeWe will determine whether treatment with a proprietary rILanalog plus an antitumor antigen antibody can safely and effectively eradicate established tumors in mice